Compare Novavax Inc (NVAX) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs DENTSPLY SIRONA Inc — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: Novavax Inc and DENTSPLY SIRONA Inc are close in size by market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| NVAX | XRAY | |
|---|---|---|
Market Cap | $1.82B | $1.73B |
Volume | 6,198,505 | 6,198,582 |
Sector | Health | Health |
52-Week High | $12.75 | $14.68 |
52-Week Low | $6.22 | $8.52 |
Typical Hold Time | 59 Days | 72 Days |
Enterprise Value | $1.39B | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
DENTSPLY SIRONA (XRAY) trades at $8.69, down 1.76% on the day and near a 52-week low, reflecting ongoing operational challenges. The stock shows a bearish technical trend with weak moving averages, while fundamentals reveal declining revenue, negative net income margins, and elevated debt levels. Recent Q2 2026 earnings beat expectations but sales fell 4.1%, indicating persistent headwinds in dental markets.
The outlook remains cautious due to margin pressure and competitive threats, though analyst consensus suggests upside to a $13.40 price target. Key risks include execution of the turnaround plan, macroeconomic sensitivity, and high leverage. Investment appeal hinges on successful restructuring and recovery in core dental segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
